GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Bukwang Pharm Co 003000.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

3,825

+0.66%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩200.71bn

FY2016FY2025

Net income

₩12.56bn

FY2016FY2025

Free cash flow

₩10.27bn

FY2016FY2025

Shareholders' equity

₩340.60bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₩200.71bn₩160.09bn₩125.93bn₩190.91bn₩182.49bn₩169.66bn₩168.19bn₩194.22bn₩150.74bn₩138.62bn
Gross profit₩91.91bn₩74.34bn₩47.07bn₩79.43bn₩75.76bn₩71.64bn₩84.25bn₩115.01bn₩80.63bn₩76.29bn
Research and development₩19.40bn₩23.43bn₩34.55bn₩24.27bn₩22.46bn₩18.03bn₩17.31bn₩24.64bn₩25.07bn₩18.68bn
Operating income₩14.16bn₩1.62bn—−₩230.6m₩5.62bn₩4.03bn₩9.54bn₩35.13bn₩7.68bn₩8.54bn
Net income₩12.56bn−₩2.64bn−₩31.33bn−₩2.47bn−₩916.6m−₩7.20bn−₩7.41bn₩145.67bn₩11.09bn₩15.81bn
Diluted earnings per share196.22-41.27-489.54-38.67-14.32-112.55-115.822,183.70188.70293.38

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₩476.29bn₩373.18bn₩429.02bn₩400.93bn₩397.42bn₩400.97bn₩388.53bn₩493.62bn₩236.23bn₩237.63bn
Total liabilities₩135.36bn₩129.03bn₩194.75bn₩129.08bn₩117.36bn₩129.78bn₩62.05bn₩80.17bn₩24.93bn₩23.00bn
Debt—₩79.02bn₩78.53bn———————
Shareholders' equity₩340.60bn₩243.68bn₩226.31bn₩263.22bn₩269.61bn₩258.50bn₩326.25bn₩413.41bn₩211.30bn₩214.63bn
Shares outstanding64m64m64m64m64m64m64m67m59m54m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations₩21.46bn₩34.36bn−₩9.36bn₩16.46bn₩26.52bn₩723.2m−₩23.41bn₩6.82bn₩8.56bn−₩7.76bn
Capital spending−₩11.19bn−₩2.61bn−₩2.83bn−₩4.99bn−₩785.1m−₩1.92bn−₩3.54bn−₩3.71bn−₩4.49bn−₩5.93bn
Free cash flow₩10.27bn₩31.75bn−₩12.20bn₩11.47bn₩25.74bn−₩1.19bn−₩26.95bn₩3.11bn₩4.08bn−₩13.69bn
Dividends paid−₩4.93bn——−₩6.85bn−₩6.23bn−₩12.19bn−₩9.77bn−₩8.61bn−₩17.94bn−₩22.81bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩56.99bn₩47.78bn₩62.51bn₩47.81bn₩42.58bn₩47.81bn₩46.18bn₩42.60bn
Gross profit₩24.40bn₩19.00bn₩32.78bn₩19.45bn₩18.78bn₩20.90bn₩21.37bn₩20.27bn
Operating income₩1.41bn₩1.10bn₩8.16bn₩979.1m—₩3.01bn₩1.95bn₩3.18bn
Net income₩1.40bn₩1.18bn₩4.67bn₩1.53bn₩6.43bn−₩69.1m₩1.85bn₩155.0m
Diluted earnings per share21.8918.4072.9623.92100.42-1.0828.862.42
Cash from operations₩2.78bn−₩1.49bn₩10.43bn−₩6.24bn₩10.03bn₩7.24bn₩11.53bn₩9.06bn
Capital spending−₩2.80bn−₩2.47bn−₩2.61bn−₩1.84bn−₩2.80bn−₩3.94bn−₩1.06bn−₩1.11bn
Free cash flow−₩19.0m−₩3.96bn₩7.82bn−₩8.08bn₩7.23bn₩3.31bn₩10.47bn₩7.96bn
Total assets₩467.05bn₩469.60bn₩476.29bn₩472.99bn₩382.92bn₩372.64bn₩373.18bn₩348.80bn
Debt———₩49.39bn₩79.26bn₩79.14bn₩79.02bn₩78.87bn
Shareholders' equity₩334.13bn₩333.50bn₩340.60bn₩340.45bn₩250.08bn₩243.31bn₩243.68bn₩224.47bn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue1.7%3.4%3.5%
Operating income—28.6%-4.9%
Net income——-6.7%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin46.1%43.2%42.7%48.2%
Operating margin4.4%———
Net margin2.7%-3.5%-3.1%8.7%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings19.3-111.2-12.5-226.3-900.7-249.7-112.69.883.354.5
Price to sales1.21.83.12.94.510.65.07.46.16.2

Dividends and splits

Per share, in the currency the company pays

Paid for 1 years. Last went ex-dividend on 4 Nov 2025.

FY2025FY2022FY2020FY2019FY2018FY2017FY2016FY2015
Paid in the year50.0090.39882.18173.16133.20121.091252.273321.075
  • 11-for-10 split · 29 Dec 2020
  • 21-for-20 split · 27 Dec 2019
  • 13-for-10 split · 27 Dec 2018
  • 11-for-10 split · 27 Dec 2017
  • 6-for-5 split · 28 Dec 2016
  • 11-for-10 split · 29 Dec 2015

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.